Navidea Biopharmaceuticals Inc (OTCPK:NAVB)

$ 0.0001 0 (0%) Market Cap: 10,000.00 Enterprise Value: -2.60 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q4 2022 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Mar 21, 2023

$0.3399 (+12.18%)

Earnings
Q3 2022 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Nov 15, 2022

$0.2759 (+2.97%)

Earnings
Q2 2022 Navidea Biopharmaceuticals Inc Earnings Call and Business Update Transcript
Sep 08, 2022

$0.2939 (-12.16%)

Earnings
Q1 2022 Navidea Biopharmaceuticals Inc Earnings Call Transcript
May 12, 2022

$0.72 (-7.10%)

Earnings
Navidea Biopharmaceuticals Inc To Discuss Company Strategy and Clinical Update Call Transcript
Apr 20, 2022
Navidea Biopharmaceuticals Inc Business Update Financing Call Transcript
Apr 14, 2022
Q4 2021 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Mar 23, 2022

$0.92 (+2.72%)

Earnings
Navidea Biopharmaceuticals Inc At Business Update Call Transcript
Dec 16, 2021
Q3 2021 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Nov 10, 2021

$1.44 (+2.86%)

Earnings
Navidea Biopharmaceuticals Inc Annual Shareholders Meeting Transcript
Sep 14, 2021
Q2 2021 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Aug 11, 2021

$1.7 (+2.41%)

Earnings
Q1 2021 Navidea Biopharmaceuticals Inc Earnings Call Transcript
May 11, 2021

$1.63 (+1.87%)

Earnings
Q4 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Mar 24, 2021

$2.06 (-6.36%)

Earnings
Q3 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Nov 12, 2020

$2.24 (-0.44%)

Earnings
Navidea Biopharmaceuticals Inc Annual Shareholders Meeting Transcript
Sep 10, 2020
Q2 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Aug 13, 2020

$3.17 (+9.69%)

Earnings
Navidea Biopharmaceuticals, Inc. - Virtual Investor Fireside Chat Series Transcript
Jun 16, 2020
Navidea Biopharmaceuticals, Inc. - Special Call Transcript
May 21, 2020
Q1 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
May 14, 2020

$0.9614 (+0.09%)

Earnings
Q4 2019 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Mar 11, 2020

$0.9598 (-3.20%)

Earnings
Q3 2019 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Nov 07, 2019

$0.9 (+4.65%)

Earnings
Navidea Biopharmaceuticals, Inc. - Special Call Transcript
Oct 29, 2019
Q2 2019 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Aug 08, 2019

$0.59 (+5.36%)

Earnings
Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call Transcript
May 08, 2019

$2.35 (-4.08%)

Earnings
Navidea Biopharmaceuticals, Inc - Special Call Transcript
Apr 08, 2019
Q4 2018 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Mar 07, 2019

$3.4 (+4.94%)

Earnings

Navidea Biopharmaceuticals, Inc - Special Call Transcript

Apr 08, 2019 / 09:00PM GMT

Release Date Price: $3.4 (+21.43%)

Transcript

Operator

Greetings, and welcome to the Navidea Biopharmaceuticals FDA update on rheumatoid arthritis trial call. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the conference over to your host, Jed Latkin, the CEO. Mr. Latkin, you may begin.

Jed A. Latkin

Navidea Biopharmaceuticals, Inc - CEO, COO, CFO, Secretary, Treasurer & Director

Thank you, Omar. Good afternoon, and welcome, everyone, to Navidea's conference call to discuss the press release that we issued this morning concerning a clinical update regarding our rheumatoid arthritis clinical trial design.

I'm Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. This call will provide further commentary and details concerning today's press release. Following our prepared remarks, we will open up the conference call to a question-and-answer session.

With me on our call today are several members of the Navidea senior management team, including Chief Medical Officer, Dr. Michael Rosol, and our Chief Compliance and Regulatory Officer

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.